Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Empriver
San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Empriver is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment of cancer and inflammatory diseases. The company's lead program targets the prostaglandin E receptor 4 (EP4), a key mediator in the tumor microenvironment that promotes immune evasion and tumor growth. By inhibiting EP4, Empriver aims to restore the immune system's ability to recognize and attack cancer cells, particularly in treatment-resistant solid tumors. The company is currently advancing its lead candidate through early-phase clinical trials both as a monotherapy and in combination with existing immunotherapies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Empriver.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Empriver.